iRECIST: how to do it
Abstract Background iRECIST for the objective monitoring of immunotherapies was published by the official RECIST working group in 2017. Main body Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multipl...
Main Authors: | Thorsten Persigehl, Simon Lennartz, Lawrence H. Schwartz |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | Cancer Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40644-019-0281-x |
Similar Items
-
Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
by: Hongge Liang, et al.
Published: (2020-04-01) -
Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
by: Peng Song, et al.
Published: (2019-04-01) -
Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Hyo Jung Park, et al.
Published: (2021-01-01) -
Are radiologists ready to evaluate true response to immunotherapy?
by: Inci Kizildag Yirgin, et al.
Published: (2021-02-01) -
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
by: Wenxiao Jia, et al.
Published: (2019-12-01)